Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.
Key Points
Gilead's HIV therapies generate strong free cash flow.
The company is successfully branching out into oncology and anti-inflammatory therapies.
Cancer therapy Trodelvy reported a sales rise of 42%, year over year in the third quarter.
- Motley Fool Issues Rare "Total Conviction" Buy Alert ›
Gilead Sciences (NASDAQ: GILD) is the leading pharmaceutical company that produces HIV treatments. Its chronic HIV management therapies are largely insulated from macroeconomic downturns because of how crucial they are to those with the disease.
Gilead raised its quarterly dividend by 3.8% this year to $0.82, the 11th consecutive year it has increased its dividend. The dividend yield, at Gilead's current share price, is around 1.9%, nearly double the S&P 500 (SNPINDEX: ^GSPC) average. The company has increased its dividend by just under 75% over the past decade.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Gilead is in a great position to continue raising its dividend. Let's see why.
Image source: Getty Images.
Its free cash flow easily covers its dividend
Gilead's cash dividend payout ratio is only 29.8%, indicating it has ample room to maintain its dividend and fund other operations.
The driver of that cash is the company's HIV franchise. In the third quarter, the company reported $8.3 billion in revenue, up 13% year over year, led by 18% higher HIV sales compared to the same period a year ago and HIV prevention therapies, whose sales nearly doubled year over year.
Over nine months, the company reported $10.6 billion in free cash flow, up 68% year over year.
Its efforts to broaden its portfolio are paying off
In recent years, Gilead has expanded into oncology and anti-inflammatory treatments. It just opened a new research center to grow its oncology, inflammation, and research data science, and it has said it plans to spend $32 billion in projects through 2030 to support research.
Trodelvy, used to treat bladder cancer and breast cancer, brought in $506 million in the third quarter, up 42% year over year. The drug was also recently approved as a combination therapy with Keytruda, made by Merck, as a first-line treatment for a very aggressive form of breast cancer.
The company also has more than a dozen inflammation and immunology drugs in clinical testing, most notably emvistegrast, which recently showed a 66% response rate in patients with ulcerative colitis.
Should you buy stock in Gilead Sciences right now?
Before you buy stock in Gilead Sciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $342,020!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,270,017!*
Now, it’s worth noting Stock Advisor’s total average return is 885% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 5, 2026.
James Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Gilead Sciences and Merck. The Motley Fool has a disclosure policy.
Recommended Articles
